Onkologie. 2009:3(2):111-113

Principles of therapy inside the oral cavity in patients treated with bisphosphonates

doc. MUDr. Milan Machálka, CSc, MUDr. Oliver Bulik, Ph.D
Klinika ústní, čelistní a obličejové chirurgie, Brno-Bohunice

Comprehensive treatment with bisphosphonates in patients suffering from either oncogenous diseases or osteoporosis may adversely

affect the bone tissue of the jaw and thus, osteonecrosis might occur after teeth extractions or other surgical interventions. Bone wounds

would not heal up and necrotic bone edges are exposed into the oral cavity. At first the treatment of the affected area is performed in

a considerate conservative way, later on surgical treatment and removal of necrotic and disengaging bone parts is carried out. Targeted

compound antibiotic medication is indicated on account of the prevalence of anaerobic microflora present in the area. Like in oncogenous

patients in whom the jaw is going to be treated with radiotherapy, thorough stomatological examination and indicated teeth extractions

are necessary to be accomplished from the preventive time point of view before the scheduled treatment with bisphosphonates

is going to start. Treatment of complications is carried out by specialists, i. e. maxillofacial surgeons.

Keywords: osteonecrosis of the jaw, bisphosphonates, preventive and treatment procedures.

Published: April 1, 2009  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Machálka M, Bulik O. Principles of therapy inside the oral cavity in patients treated with bisphosphonates. Onkologie. 2009;3(2):111-113.
Download citation

References

  1. Marx RE. Pamidronate (Aredia) and zolendronate (Zometa) induced avascular necrosis of the jaw: A growing epidemic. J Oral Maxillofac Surg 2003; 61: 1115-1117. Go to original source... Go to PubMed...
  2. Adam Z, Machálka M, Kozumplíková M, et al. Osteonekróza čelisti v průběhu léčby při komplexní léčbě mnohočetného myelomu obsahující bisfosfonáty. Vnitř Lék 2006; 52: 176-180. Go to PubMed...
  3. Badros A, Weikel D, Salama A, et al. Osteonecrosis of the jaw in multiple myeloma patients: Clinical features and risk factors. J Clin Oncol 2006; 24: 945-952. Go to original source... Go to PubMed...
  4. Greenberg MS. Intravenous bisphosphonates and osteonecrosis. Oral Surg Oral Med Oral Pathol Radiol Endod 2004; 98: 259-260. Go to original source... Go to PubMed...
  5. Khan AA, Sándor GKB, Dore E, et al. Canadian consensus practice guidelines for bisphosphonate associated osteonecrosis of the jaw. J Rheumatol 2008; 35: 1-7.
  6. Machálka M. Osteonekróza čelisti po komplexní léčbě nádorů bisfosfonáty. Vnitř Lék 2006; 52(S2): 79-82.
  7. Ruggiero SL, Mehrotra B, Rosenberg TJ, et al. Osteonecrosis of the jaws associated with the use of bisphosphonates: A review of 63 cases. J Oral Maxillofac Surg 2004; 62: 527-534. Go to original source... Go to PubMed...
  8. Ruggiero SL, Fantasia J, Carlson E. Bisphosphonate-related osteonecrosis of the jaw: Background and guidelines for diagnosis, staging and management. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2006; 102: 433-441. Go to original source... Go to PubMed...
  9. Advisory task force on bisphosphonate-related osteonecrosis of the jaws. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg 2007; 65: 369-376.




Oncology

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.